drugset / Trial / NCT07138209

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT07138209

Phase 3 Recruiting 228 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.

Timeline

Start
2025-11-07
Primary completion
2027-12
Completion
2029-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pomalidomide Other / unclassified Oral
Subject QLS32015 Unknown Subcutaneous
Subject Selinexor Other / unclassified Oral
Background Dexamethasone Small molecule Oral